Browse the evidence

Genetic proxies for body weight reduction via GIP receptor targeting reduces the risk of MACE and heart failure, mediated partly through lower BMI and partly through lower HbA1c.

Understanding GIP receptor pathways can inform strategies for reducing cardiovascular risks.

Semaglutide users experienced modest weight reductions ranging from 0.42 kg to 1.16 kg.

Practitioners may consider Semaglutide for modest weight loss in type 2 diabetes management.

The study identified key themes for safe practices in BMT, including psychological health, sleep apnea, cardiovascular disease, liver health, and dietetic assessment.

Practitioners should consider these health factors when evaluating patients for BMT.

Lifestyle intervention alone is typically associated with approximately 2%-5% weight loss at 1 year of follow-up.

Practitioners should set realistic weight loss expectations for patients relying solely on lifestyle changes.

Bariatric surgery has the greatest degree of expected weight loss, at around 20%-30% at 1 year.

Bariatric surgery may be the most effective option for patients needing significant weight loss.

Menopause is associated with weight gain and a predisposition to obesity in women.

Practitioners should be aware of the increased risk of weight gain in menopausal women.

Women begin to lose lean mass during menopause, leading to an increase in fat mass.

Practitioners should monitor body composition changes in menopausal women.

Targeted antiobesity medications (AOM) have demonstrated significant weight loss and improved quality of life in patients with specific genetic obesity disorders.

Practitioners should consider targeted AOMs for patients with genetic obesity disorders to improve weight management and quality of life.

Nontargeted AOMs can achieve similar benefits in patients with specific genetic obesity disorders compared to common multifactorial obesity.

Practitioners may consider nontargeted AOMs as an alternative for managing obesity in patients with genetic disorders.

GLP-1RA-induced weight loss would lead to a marked decrease in cancer cases over 10 years in adults.

Implementing GLP-1RA treatments could significantly reduce cancer incidence in obese populations.

If GLP-1RAs were made available for all people with obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 21,443.

Wider access to GLP-1RAs could lead to significant reductions in cancer cases among obese individuals.

Significant reductions in diastolic BP (-1.5 mm Hg) and systolic BP (-1.1 mm Hg) were observed.

Semaglutide may help lower blood pressure in adults.

The introduction of a Disease Management Program for obesity could significantly improve the quality of care for affected individuals.

Implementing a Disease Management Program could enhance care quality for individuals with obesity.

GLP-1 receptor agonists promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.

GLP-1 receptor agonists can be considered for managing type 2 diabetes and obesity in clinical practice.

GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes.

Consider GLP-1 receptor agonists for patients at high risk of cardiovascular issues or renal failure.

The preoperative weight loss intervention was feasible and viewed favorably among patients, with 83% feeling that video calls were helpful.

Practitioners can consider using video consultations as a supportive tool for weight loss interventions.

The unique combination of naltrexone and bupropion in NB-ER may work together to target POMC cells to prevent endogenous negative feedback, thereby decreasing appetite.

Understanding the mechanism can help practitioners explain the treatment's effects to patients.

Tirzepatide has potential impacts on diabetes, obesity, NASH, and cardiovascular risks.

Tirzepatide may be beneficial for patients with diabetes and associated comorbidities.

Metabolic adaptation hinders the efficacy of obesity management strategies.

Understanding metabolic adaptation can help practitioners develop more effective obesity management strategies.

Reinitiating semaglutide at the target dose after a treatment gap can lead to adverse effects.

Caution is advised when reinitiating GLP-1 therapy after a gap, especially at target doses.

Therapy lapses with GLP-1 receptor agonists may be prevented by a multi-modal approach.

Implementing a multi-modal strategy can help maintain GLP-1 therapy adherence.

Bariatric surgery is a highly effective intervention to induce weight loss with durability over 10 or more years.

Bariatric surgery can be considered a long-term solution for significant weight loss.

Prevention of overweight and obesity is crucial and should be addressed socially.

Efforts to prevent obesity should involve community and societal strategies.

HEC-CG115 reduced fasting blood glucose and glycated haemoglobin levels similar to those after semaglutide.

HEC-CG115 may provide effective glycaemic control for patients with type 2 diabetes.